Purple Biotech (PPBT) Income from Continuing Operations (2014 - 2026)
Purple Biotech's (PPBT) quarterly Income from Continuing Operations came in at 2200000.0 in Q1 2026, up 67.05% year-on-year from 1317000.0 in Q1 2025, and down 90.5% on a QoQ basis from 23153000.0 in Q4 2025.
Purple Biotech (PPBT) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 13 years of Income from Continuing Operations data on file, last reported at 2200000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 67.05% year-over-year to 2200000.0 in Q1 2026; TTM through Mar 2026 was 27813000.0, a 311.98% increase from a year earlier, with the FY2025 full-year figure at 26386000.0, down 261.55% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 2200000.0, down from 23153000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for PPBT reached as high as 23153000.0 in Q4 2025 and fell as low as 629000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 4789000.0 across 5 years, with a median of 4354000.0 in 2024.
- Across the five-year window, Income from Continuing Operations plunged 89.98% in 2024 and surged 3580.92% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 6043000.0 in 2022, then gained by 3.91% to 6279000.0 in 2023, then plunged by 89.98% to 629000.0 in 2024, then jumped by 3580.92% to 23153000.0 in 2025, then sank by 90.5% to 2200000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 2200000.0 in Q1 2026, 23153000.0 in Q4 2025, and 1239000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Purple Biotech | 1.31 Bn | 1.31 Bn | - | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | 23.15 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 629,000.00 |
| Sep 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | 4.35 Mn |
| Dec 31, 2023 | 6.28 Mn |
| Sep 30, 2023 | 5.02 Mn |
| Jun 30, 2023 | 4.86 Mn |
| Mar 31, 2023 | 4.79 Mn |
| Dec 31, 2022 | 6.04 Mn |
| Sep 30, 2022 | 4.82 Mn |
| Jun 30, 2022 | 3.45 Mn |
| Mar 31, 2022 | 7.23 Mn |
| Dec 31, 2021 | 7.57 Mn |
| Sep 30, 2021 | 2.95 Mn |
| Jun 30, 2021 | 3.44 Mn |